Literature DB >> 20842024

Epidemiology and pattern of care of breakthrough cancer pain in a longitudinal sample of cancer patients: results from the Cancer Pain Outcome Research Study Group.

Maria Teresa Greco1, Oscar Corli, Mauro Montanari, Silvia Deandrea, Vittorina Zagonel, Giovanni Apolone.   

Abstract

OBJECTIVE: Breakthrough cancer pain (BTcP) is a frequent event in cancer patients, with a prevalence from 19% to 95%. The reasons for such variability are explained by several factors, including different definitions across studies. In the framework of a wider initiative, we have analyzed the epidemiology of BTcP and identified factors associated with the pattern of care.
METHODS: This study reports the results from a multicenter, prospective, nonrandomized, longitudinal study carried out in Italy between 2006 and 2007 on patients with cancer and pain. Transient exacerbations of pain were assessed with 3 different questions, and 1 composite variable to operationally define BTcP was then used as main outcome. After univariate analysis, a logistic model was also fitted to identify prognostic and predictive factors.
RESULTS: One hundred and ten centers recruited 1801 cases of which 40.3% had BTcP at baseline. Most patients did not receive rescue therapy at the time of study inclusion. Univariate analysis identified several associations with clinical variables. A strong association has been also found with the type of recruiting centers, with oncologic wards reporting a somewhat lower proportion of patients with BTcP (-30%) when compared with palliative centers. Patients with BTcP had a high probability of dying (OR=1.4, 95% CI: 1.1-1.7, P-value 0.006) and to change of the opioid with another for analgesic failure or for side effects (OR=1.4, 95% CI: 1.0-1.9, P-value 0.040) DISCUSSION: These findings confirm the high prevalence of BTcP and substantial undertreatment and identify a few factors associated with prevalence and prognosis.

Entities:  

Mesh:

Year:  2011        PMID: 20842024     DOI: 10.1097/AJP.0b013e3181edc250

Source DB:  PubMed          Journal:  Clin J Pain        ISSN: 0749-8047            Impact factor:   3.442


  28 in total

1.  Treatment of cancer pain: Spanish Society of Medical Oncology (SEOM) recommendations for clinical practice.

Authors:  Juan A Virizuela; Yolanda Escobar; Javier Cassinello; Pablo Borrega
Journal:  Clin Transl Oncol       Date:  2012-07       Impact factor: 3.405

2.  Diagnosis and management of breakthrough cancer pain: Have all the questions been resolved? A Delphi-based consensus assessment (DOIRON).

Authors:  J Porta-Sales; C Pérez; Y Escobar; V Martínez
Journal:  Clin Transl Oncol       Date:  2015-12-22       Impact factor: 3.405

3.  CB1 and CB2 receptor agonists promote analgesia through synergy in a murine model of tumor pain.

Authors:  Iryna A Khasabova; James Gielissen; Anisha Chandiramani; Catherine Harding-Rose; Desiree Abu Odeh; Donald A Simone; Virginia S Seybold
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

4.  Comment on 'What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain: Expert Opinion'.

Authors:  Raffaele Giusti; Lucilla Verna; Daniela Iacono; Agnese Vannini; Corrado Ficorella; Giampiero Porzio
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

5.  The use of low doses of a sublingual fentanyl formulation for breakthrough pain in patients receiving low doses of opioids.

Authors:  Sebastiano Mercadante; Claudio Adile; Arturo Cuomo; Federica Aielli; Franco Marinangeli; Alessandra Casuccio
Journal:  Support Care Cancer       Date:  2016-10-15       Impact factor: 3.603

Review 6.  Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group.

Authors:  Sebastiano Mercadante; Paolo Marchetti; Arturo Cuomo; Massimo Mammucari; Augusto Caraceni
Journal:  Support Care Cancer       Date:  2015-10-05       Impact factor: 3.603

7.  Morphine stimulates cancer progression and mast cell activation and impairs survival in transgenic mice with breast cancer.

Authors:  J Nguyen; K Luk; D Vang; W Soto; L Vincent; S Robiner; R Saavedra; Y Li; P Gupta; K Gupta
Journal:  Br J Anaesth       Date:  2014-05-26       Impact factor: 9.166

8.  Incidence of severe pain in newly diagnosed ambulatory patients with stage IV cancer.

Authors:  Thomas Isaac; Sherri O Stuver; Roger B Davis; Susan Block; Jane C Weeks; Donna L Berry; Saul N Weingart
Journal:  Pain Res Manag       Date:  2012 Sep-Oct       Impact factor: 3.037

9.  Canadian recommendations for the management of breakthrough cancer pain.

Authors:  P Daeninck; B Gagnon; R Gallagher; J D Henderson; Y Shir; C Zimmermann; B Lapointe
Journal:  Curr Oncol       Date:  2016-04-13       Impact factor: 3.677

Review 10.  A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients.

Authors:  Evelien J M Kuip; Maarten L Zandvliet; Stijn L W Koolen; Ron H J Mathijssen; Carin C D van der Rijt
Journal:  Br J Clin Pharmacol       Date:  2016-10-29       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.